WonderTx
ActiveAI-nativeExtrapolative AI to unlock First-in-Class drugs
What it does
We’re an AI-native biotech, working on replacing needles with pills. Many drugs, like insulin or Ozempic, are wonderful except you have to inject them. We discover new molecules that you can take as a pill instead. Because the pills operate on biology which has been shown to be effective in people, rather than merely in animal models of disease, we avoid what has historically been the single biggest risk in drug discovery. This should dramatically increase our probability of success. There’s $200B of treatable diseases and validated human biology without a pill because discovery programs lack a tractable chemical starting point. This is a zero-shot inference problem, because these targets have no training data, so LLMs and other historical interpolative AI approaches are insufficient. Instead, we are building our own extrapolative frontier models that reason beyond their training data. Most critically, we have repeatedly validated our platform on both our own and partner programs. On 4 biologically- and structurally-diverse targets where we had zero training data, we successfully picked binders that were validated experimentally, with confirmation ranging from primary screen hits to crystallographic structures.
Next to it in Healthcare and bio · AI-powered oral drug discovery
- ConvexiaY Combinator S25
The world's first AI-maximalist pharma company
- Ditto BiosciencesY Combinator W26
Evolutionary intelligence for autoimmune disease
- PaulingPlug and Play PnP 2025
Next-generation molecular simulation platform for drug discovery.
- RasynY Combinator S26
Towards a General Intelligence for Chemistry
- Axiom TherapeuticsPlug and Play PnP 2025
AI-powered covalent drug discovery for untreatable cancers
- CytodymeTechstars TS 2025
Cytodyme
- Ångström AIY Combinator S24
Gen AI molecular simulations that reproduce wetlab results
- AMPLY DiscoveryTechstars TS 2023
AMPLY Discovery — Turning the Dark Genome into Novel Medicines